IVIG Side Effects: Common Reactions and Serious Risks

Most IVIG (intravenous immunoglobulin) infusions are well tolerated, and the side effects that do occur tend to be mild and short-lived: headache, chills, flushing, fatigue, and low-grade fever are the most frequently reported reactions. But IVIG is not a simple drug. It is a concentrated pool of antibodies drawn from thousands of blood donors, and the list of possible adverse effects extends well beyond those common nuisances to include kidney damage, blood clots, destruction of red blood cells, and even a form of temporary meningitis. Understanding where you fall on the risk spectrum, and what can be done to reduce that risk, matters a great deal if you are starting or continuing this therapy.

Common Infusion Reactions

The reactions you are most likely to experience during or shortly after an IVIG infusion are the ones nurses and patients casually call “infusion reactions.” These include flushing, headache, malaise, fever, chills, fatigue, and lethargy, and they are generally transient and mild.¹ One hospital-based study found that adverse reactions occurred in only about 1% of all IVIG infusions administered, with fever being the single most common symptom, followed by skin changes and rash, then headache.² That low overall rate can be reassuring, though rates vary depending on the patient population, the underlying disease being treated, the specific IVIG product, and the speed of infusion.

These mild reactions typically respond well to simple measures. Slowing or briefly pausing the infusion often resolves symptoms on its own. When that is not enough, analgesics, antihistamines, or in more stubborn cases a short course of a corticosteroid can help.³ For many patients, these reactions diminish over time as their body adjusts to repeated infusions.

Headaches and Aseptic Meningitis

Headache deserves its own discussion because it is both the most common complaint and, in its severe form, a gateway to the more alarming complication of aseptic meningitis. In a long-term study tracking over 9,000 IVIG infusions, headache occurred in about 13% of patients during the initial high-dose loading period.⁴ It is often the symptom that bothers patients most and the one that most frequently prompts requests to adjust treatment.

Aseptic meningitis is an inflammation of the membranes surrounding the brain that is not caused by a bacterial or viral infection. It typically appears within 24 hours of completing a high-dose infusion and presents with severe headache, stiff neck, sensitivity to light, nausea, and sometimes fever. In one study of 54 patients receiving high-dose IVIG, about 11% developed aseptic meningitis. That study also identified a striking risk factor: half of patients who had a history of migraine developed aseptic meningitis, compared with only about 4% of those without migraines. The meningitis recurred in migraine-prone patients even when different IVIG brands were used and infusion rates were slowed.⁵ Symptoms typically last three to five days and resolve on their own. No deaths from IVIG-induced aseptic meningitis have been reported.⁶

The challenge with aseptic meningitis is that its symptoms look a lot like actual infectious meningitis, so doctors need to do a spinal tap to rule out a real infection before they can confidently call it a drug side effect. If you develop a severe headache with neck stiffness after an IVIG infusion, it needs prompt evaluation regardless of the likely cause.

Blood Clots

IVIG increases blood viscosity, and that raises the risk of clots forming in both arteries and veins. A study of patients with blood cancers found a transiently increased risk of arterial clot events on the day of infusion and the day afterward, with a hazard ratio of about 3.4 compared to non-infusion days. Averaged over an entire year of monthly treatments, the additional absolute risk attributable to IVIG was estimated at roughly 0.7% above a baseline arterial clot risk of about 1.8%. The increase in venous clot risk was smaller and did not reach statistical significance.⁷

In practical terms, the clot risk is highest in the first day or two after treatment and matters most for people who already carry cardiovascular risk factors. Adequate hydration before and after the infusion, along with slower infusion rates, are considered key strategies for keeping blood viscosity in check.⁸ If you have a history of stroke, heart disease, or prior clots, your doctor should weigh that risk carefully when deciding on IVIG dosing and scheduling.

Heart Failure and Volume Overload

IVIG is administered as a large volume of protein-rich fluid, and for patients whose hearts are already compromised, that fluid load can tip the balance toward heart failure. A systematic review of IVIG use in neurological conditions found that both patients who developed cardiac complications during treatment had preexisting heart disease; the volume overload from the infusion worsened their existing heart failure. In one study of 50 patients with neuromuscular disorders, the incidence of IVIG-associated heart failure reached 10%.⁹ This is not a concern for most recipients, but people with known cardiac problems, particularly those whose underlying neurological conditions also affect the heart, need careful fluid management during treatment.

Kidney Damage

Acute kidney injury is an uncommon but well-documented IVIG complication, and the culprit in most cases is sucrose. Many IVIG formulations use sucrose as a stabilizer to prevent the immunoglobulin molecules from clumping together. The kidneys cannot metabolize sucrose efficiently; when large amounts arrive in the proximal tubules, they cause osmotic swelling and injury to the tubular cells, a pattern known as osmotic nephropathy.¹⁰ Kidney biopsies in affected patients consistently show this distinctive pattern of osmotic damage.¹¹

Several factors raise your risk: older age, pre-existing kidney disease, diabetes, dehydration, and concurrent use of other drugs that stress the kidneys. For high-risk patients, guidelines recommend choosing a sucrose-free IVIG product, ensuring good hydration before and during infusion, using a slower drip rate, and monitoring kidney function throughout treatment.¹² In one study of patients aged 60 and older with neuromuscular diseases, roughly a third experienced adverse reactions overall, and kidney failure was among the serious events observed. Interestingly, the use of sucrose-free IVIG in that older group was independently associated with a different pattern of side effects, underscoring how much the specific product formulation matters.¹³

Hemolytic Anemia

This one catches many patients off guard. Because IVIG is pooled from thousands of donors, it inevitably contains antibodies against blood group antigens, particularly anti-A and anti-B. If your blood type is A, B, or AB, those donor antibodies can latch onto your red blood cells and destroy them, a process called hemolysis. People with blood type O are largely spared because their red cells lack the A and B antigens that the antibodies target.¹⁴

In one study of 42 patients receiving IVIG, 12 developed detectable antibodies against their own blood group antigens, and 11 of those had clinically significant hemolysis with a drop in hemoglobin of at least 1 g/dL. Three patients needed blood transfusions, and one had to stop IVIG treatment because of it.¹⁵ This effect is dose-dependent and more common with the high doses used in autoimmune and inflammatory conditions than with the replacement doses used for immune deficiency. Your treatment team should monitor blood counts after infusions, especially in the first few cycles.

Lung Injury

Transfusion-related acute lung injury, or TRALI, is rare but can be life-threatening. It involves sudden respiratory distress, low oxygen levels, and fluid in the lungs, usually within hours of an infusion. The current understanding follows a “two-hit” model: the patient’s underlying condition creates a primed, inflammatory state in the lungs (the first hit), and then something in the infused product, whether donor antibodies against the recipient’s white blood cells or non-antibody factors like lipids and proteins, delivers the second hit that triggers the full-blown reaction.¹⁶ TRALI is recognized as a possible serious adverse effect of IVIG, though the incidence is very low.¹⁷

Anaphylaxis and IgA Deficiency

True anaphylaxis during IVIG is rare, but when it happens, one well-studied trigger is IgA. A small fraction of patients have very low or undetectable levels of IgA in their blood and have developed IgG antibodies against IgA. When these patients receive standard IVIG, which contains trace amounts of IgA, those anti-IgA antibodies can trigger a severe allergic reaction. In a cohort of 22 IgA-deficient patients receiving immunoglobulin therapy, three had IgG anti-IgA antibodies, and the one who had received intravenous infusion had experienced anaphylaxis requiring epinephrine.¹⁸ For patients with known IgA deficiency, IVIG products with the lowest possible IgA content are preferred, and the first infusion should be given with close monitoring and emergency equipment on hand.

Skin Reactions Beyond Rashes

Aside from the ordinary rashes that fall under mild infusion reactions, IVIG has been linked to a specific and annoying skin condition: pompholyx, also called dyshidrotic eczema. This presents as clusters of small, intensely itchy blisters on the palms and sometimes the soles of the feet. Case reports have documented it appearing after only the second dose of IVIG in a patient with myasthenia gravis¹⁹ and following treatment in a patient with peripheral neuropathy.²⁰ While not dangerous, pompholyx can be persistent and uncomfortable enough to affect daily life, and it is worth recognizing as IVIG-related so it can be managed rather than misdiagnosed.

Who Is at Higher Risk

Not everyone faces the same odds of experiencing side effects. Several factors consistently appear across the literature as risk amplifiers:

Older age: Elderly patients, especially those with cardiovascular risk factors or pre-existing kidney problems, are more vulnerable to the serious complications like clots, kidney injury, and heart failure.²¹
Higher doses: The high-dose regimens used in autoimmune conditions (typically 2 g/kg over several days) carry more risk than the lower replacement doses used in primary immune deficiency.
Migraine history: As noted above, a personal history of migraines dramatically raises the odds of developing aseptic meningitis.²²
Non-O blood type: Blood types A, B, and AB are at greater risk of hemolytic anemia from donor antibodies in the product.
Kidney disease or dehydration: Both increase the danger of osmotic kidney damage, especially with sucrose-containing products.
IgA deficiency: Raises the risk of serious allergic reactions including anaphylaxis.

On the reassuring side, a study of IVIG use during pregnancy found that it did not increase obstetric complications or birth defects beyond what is seen in the general population. Rates of preterm birth, gestational diabetes, and preeclampsia in the treated group were within expected ranges, and no viral contamination from the product was observed.²³

Reducing Side Effects

The most consistently recommended strategies for minimizing IVIG reactions are deceptively simple: slow the infusion rate and keep the patient well hydrated. These two measures alone help prevent not just the common infusion reactions but also the more serious complications of kidney injury, clotting, and aseptic meningitis.²⁴

For headache specifically, a range of strategies have been studied, including hydration, switching to a different IVIG brand, reducing the infusion rate, and treating prophylactically with oral painkillers, migraine medications, or propranolol. Most patients found improvement with one or a combination of these approaches.²⁵

Premedication is more nuanced than you might expect. A study of pediatric patients with immune thrombocytopenia found that acetaminophen given before infusion was associated with fewer adverse events, which makes intuitive sense. Diphenhydramine (Benadryl) showed no significant benefit. More surprising was the finding that premedication with hydrocortisone was actually associated with higher odds of side effects and a greater likelihood of the patient needing to return for additional medical care afterward.²⁶ This does not mean steroids are never appropriate for managing IVIG reactions, but it does challenge the reflex of giving them routinely as a preventive step.

What Happens with Long-Term Use

Many patients receive IVIG for months or years, which raises the question of whether side effects accumulate over time. The evidence is generally encouraging but with caveats. A ten-year safety study in patients with multiple sclerosis tracked over 9,000 infusions and found that the annual rate of adverse events was about 4.4% during the first year and trended downward in subsequent years. No severe adverse events were recorded over the entire study period.²⁷ Another study of long-term IVIG in autoimmune diseases found that mild, transient side effects persisted in about half of patients over time, but severe events were rare and occurred early in treatment rather than accumulating with more infusions.²⁸

One area that does warrant ongoing monitoring is the slow, subclinical toll on kidneys and red blood cells. A study tracking patients with neurological conditions over 12 months of IVIG therapy found that while no patient developed overt hemolysis, about a fifth had a meaningful decline in hematocrit (a measure of red blood cell volume) and about one in ten had a significant drop in kidney filtration rate.²⁹ These changes were gradual enough to be missed without regular lab work, which is why periodic blood and kidney testing is standard for patients on chronic IVIG.

The Subcutaneous Alternative

If you are struggling with IVIG side effects, one option worth discussing with your doctor is switching to subcutaneous immunoglobulin (SCIG). Instead of a large intravenous dose given every few weeks, SCIG is self-administered in smaller, more frequent doses under the skin, often weekly. Because the immunoglobulin is absorbed more gradually into the bloodstream, the peaks in serum concentration that drive many IVIG reactions are blunted. Subcutaneous IgG has a lower incidence of systemic adverse effects than intravenous delivery.³⁰ The trade-off is local injection-site reactions like redness and swelling, plus the need for more frequent self-administration. For some patients, those trade-offs are well worth avoiding the headaches, fatigue, and other systemic symptoms that come with intravenous infusions.

Product Safety and Viral Transmission

Because IVIG is derived from human plasma, a natural concern is whether it can transmit infections. Modern manufacturing processes involve multiple steps designed to inactivate and remove viruses, and the safety record is strong. No proven case of HIV transmission through immunoglobulin products has been reported.³¹ There were rare historical instances of hepatitis C transmission, which led manufacturers to add dedicated virus-inactivation steps like pasteurization (heating the solution to 60°C for 10 hours) and chemical treatments. These measures achieve at least a 100,000-fold reduction in hepatitis C and related viruses. Evaluations of manufacturing processes have confirmed that virus and prion reduction consistently meet safety standards, even at the edges of operating parameters.³² IVIG preparations carry a long safety record and a low risk of transmitting viral infections with modern production methods.³³

The Wear-Off Effect and Quality of Life

Beyond the acute side effects, many patients on chronic IVIG report a cyclical pattern in how they feel between infusions, sometimes called the “wear-off” effect. A study measuring quality of life at different time points during IVIG infusion cycles found that patients consistently rated their general health worse on the day of infusion compared to a week later. Both overall health ratings and fatigue improved by day seven after each infusion, though the two measures appeared to be independent of each other: feeling less tired did not always track with feeling healthier overall, and vice versa.³⁴

This cyclical pattern means that patients on monthly IVIG often feel their best in the week or two after an infusion and their worst in the days before the next one, as immunoglobulin levels gradually decline. It is a lived reality that does not always show up in standard side-effect statistics but significantly affects day-to-day life. Surveys of patients with primary immune deficiency have found that their physical and mental well-being scores remain below population norms even while on treatment.³⁵ Switching to more frequent, smaller-volume dosing, whether intravenous or subcutaneous, is one approach that can smooth out these peaks and troughs and improve the overall experience of being on long-term immunoglobulin therapy.